Trial Information
DAHANCA 20 Palliative Radiotherapy for Head and Neck Cancer
Inclusion Criteria:
- Incurable primary or second primary head and neck cancer
- Speaks and reads Danish
- Capable of filling out questionnaires for at leas two months after radiotherapy
- Age>=18 years
- Expected survival> 3months
Type of Study:
Interventional
Study Design:
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Outcome Measure:
Frequency and intensity of symptoms before and after radiotherapy (EORTC C30 and H&N35 questionnaires and CTC AE 3.0 toxicity scores)
Outcome Time Frame:
11 mths
Safety Issue:
No
Principal Investigator
Kenneth Jensen, MD
Investigator Role:
Principal Investigator
Investigator Affiliation:
DAHANCA (Danish Head and Neck Cancer Group)
Authority:
Denmark: The Regional Committee on Biomedical Research Ethics
Study ID:
DAHANCA 20
NCT ID:
NCT00400426
Start Date:
November 2006
Completion Date:
June 2012
Related Keywords:
- Head and Neck Neoplasms
- Recurrence
- Neoplasms, Second Primary
- Palliative radiotherapy
- Recurrent
- Head and neck Neoplasm
- Quality of life
- Neoplasms
- Head and Neck Neoplasms
- Recurrence
- Neoplasms, Second Primary